The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×

The importance of combining psychosocial and pharmacologic interventions for optimum outcome in the treatment of schizophrenia is now well recognized. However, less research is available on ways in which the two types of treatment may affect each other. This article reviews research and principles applying to the integrated use of current psychosocial and pharmacologic treatments for schizophrenia. Emphasis is placed on areas of interaction, including patient adherence and the effect of antipsychotic medications on cognitive functioning. Recommendations are presented for specific clinical situations.